BridgeMD
Clinical Trial of Immune-Guided Prevention of CMV Infection in Low-Risk Kidney Transplantation: INMUNOVIR Study.
EU CTIS ID: 2025-520742-29-00
What this study is testing
Compare the efficacy and safety of immune-guided prophylaxis versus preemptive therapy in kidney transplant recipients.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Over 18 years of age
- CMV-seropositive kidney transplant recipients
- Must have a negative pregnancy test (non-menopausal women)
You likely can't join if
- HIV-infected patients
- Patients with multivisceral transplants
- Those who are not expected to receive universal prophylaxis
- Receiving induction therapy with anti-thymocyte globulin (ATG)
- Having HLA excluded from QF-CMV
- Unable to comply with the follow-up protocol
See the full eligibility criteria
- Over 18 years of age
- CMV-seropositive kidney transplant recipients
- Must have a negative pregnancy test (non-menopausal women)
- HIV-infected patients
- Patients with multivisceral transplants
- Those who are not expected to receive universal prophylaxis
- Receiving induction therapy with anti-thymocyte globulin (ATG)
- Having HLA excluded from QF-CMV
- Unable to comply with the follow-up protocol
- Having CMV replication/disease prior to inclusion
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.